scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
pp. 257-264
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
Vol 3 (4) ◽  
pp. 257
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

scholarly journals Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Yasunori Minami ◽  
Masatoshi Kudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Safety Margin ◽  
Surgical Techniques ◽  
Evidence Base ◽  
Current Status ◽  
Probe Design ◽  
Curative Therapy ◽  
Management Of Complications ◽  
Liver Cancers

Radiofrequency ablation (RFA) of liver cancers can be performed safely using percutaneous, laparoscopic, or open surgical techniques, and much of the impetus for the use of RFA has come from cohort series that have provided an evidence base for this technique. Here, we give an overview of the current status of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), including its physical properties, to assess the characteristics that make this technique applicable in clinical practice. We review the technical development of probe design and summarize current indications and outcomes of reported clinical use. An accurate evaluation of treatment response is very important to secure successful RFA therapy since a sufficient safety margin (at least 0.5 cm) can prevent local tumor recurrences. We also provide a profile of side effects and information on the integration of this technique into the general management of patients with HCC. To minimize complications of RFA, physicians should be familiar with each feature of complication. Appropriate management of complications is essential for successful RFA treatment. Moreover, adjuvant therapy, such as molecular targeted therapies following curative therapy, is expected to further improve survival after RFA.

Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis

2021 ◽  
Vol 21 (2) ◽  
pp. 105-112
Author(s):  
Sang Jin Kim ◽  
Jong Man Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Radiation Therapy ◽  
Portal Vein ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma ◽  
Portal Vein Tumor Thrombosis ◽  
Donor Liver Transplantation ◽  
Tumor Thrombosis ◽  
Locoregional Therapies

Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed.

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

2020 ◽  
Vol 04 (02) ◽  
pp. 187-194
Author(s):  
Shauna R. Campbell ◽  
Timothy D. Smile ◽  
Sarah M.C. Sittenfeld ◽  
Kevin L. Stephans
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Effective Treatment Option ◽  
Stereotactic Body Radiation ◽  
Common Cancer ◽  
Clinical Presentations ◽  
Liver Cancers ◽  
Bridging To Transplant

AbstractPrimary liver cancer is the seventh most common cancer worldwide and is the second leading cause of cancer-related death. Hepatocellular carcinoma (HCC) accounts for three-quarters of primary liver cancers and less than a third of patients present with curable disease. Liver-directed therapy is essential for the treatment of patients with unresectable HCC and the advancement of stereotactic body radiation therapy (SBRT) has made radiation a safe and effective treatment option in a range of clinical presentations. In this review, we discuss the technical aspects of SBRT and the general approach to treatment of HCC. We explore the use of SBRT for bridging to transplant, downstaging, and the treatment of large tumors and portal vein tumor thrombus. Although there is limited high-quality randomized data, we review the evidence comparing SBRT with other liver-directed therapies and explore areas for future investigation.

scholarly journals Current status and potential perspectives in classical radiotherapy technology

2004 ◽  
Vol 57 (5-6) ◽  
pp. 241-248
Author(s):  
Kata Dabic-Stankovic ◽  
Jovan Stankovic ◽  
Ljiljana Radosevic-Jelic
Keyword(s):  
Radiation Therapy ◽  
Developed Countries ◽  
Current Status ◽  
Growing Up ◽  
Record System ◽  
Radiation Technology ◽  
The Usa ◽  
Ct And Mri

Introduction and potentials of classical radiotherapy After purchase of radiotherapy equipment in 2003, classic radiation therapy in Serbia will reach the highest world level. In order to define the highest standards in radiation technology, we analyzed the current status and potential perspectives of radiation therapy. Technological levels of radiotherapy in developed countries An analysis of present situation in the USA, assumed as the most developed in the world, was done. Available data, collected in the last 3 years (equipment assortment, therapy modalities, workload and manpower) for 284 radiotherapy centers, out of potential 2050, were analyzed. Results were presented as crude percentage and mached to point current status. Results of analysis and discussion The analysis showed that CLINAC accelerators are the most popular (82.7%), as well as, ADAC (43.7%) and Focus (CMS) (27.4%) systems for therapy planning. Movement towards virtual simulation is evident (59.3%), although classic ?simulation? is not fully eliminated from the radiotherapy chain. The most popular brachytherapy afterloader is Microselectron HDR (71%). About 64.4% centers use IMPAC communication/verification/record system that seems more open than Varis. All centers practice modern radiotherapy modalities and techniques (CFRT, IMRT, SRS/SRT, TBI, IORT, IVBHRT, HDR BHRT, etc.). CT and MRI availability is out of question, but PET is available in 3% of centers, however this percentage is rapidly growing. Up to 350 new patients per year are treated by one accelerator (about 35 pts. a day). Centers are relatively small and utilize 2-3 accelerators on average. Average FTE staffing norm is 4 radiation oncologists, 2-3 medical radiotherapy physicists, about 3 certified medical dosimetrists and about 6 radiotherapy technologists. Technological aspects and conclusion In the past 5 years relative stagnation in classic radiotherapy has been observed. In spite of substantial investments in technology and consequent improvements, as well as wide introduction of computers in radiotherapy, radiotherapy results have not changed significantly. Vendor development strategies do not point that this trend will change in the next 5 years. On the other hand, wide introduction of the PET in each radiotherapy chain ring (diagnostics, planning, follow-up), could improve results (local and regional control, as well as quality of patients' life).

Actual Problems and Perspectives of the Application of Nuclear Medicine Techniques in the Diagnostic and Treatment of Hepatocellular Carcinoma: Analytical Review

2019 ◽  
Vol 64 (5) ◽  
pp. 58-68
Author(s):  
Андрей Бушманов ◽  
Andrey Bushmanov ◽  
О. Клементьева ◽  
O. Klement'eva ◽  
А. Лабушкина ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Nuclear Medicine ◽  
Radiation Therapy ◽  
Malignant Tumors ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Distant Metastases ◽  
Diagnosis And Treatment ◽  
Traditional Methods ◽  
Early Results

In the presented review of publications, together with a brief analysis of the incidence, risk factors for the occurrence and methods of diagnosis of hepatocellular carcinoma (HCC), current problems and prospects for the application of nuclear medicine methods in the diagnosis and treatment of this disease are indicated. Hepatocellular carcinoma is one of the most common malignant tumors of the liver and is characterized by a rapidly progressing course with an unfavorable life expectancy. A variety of clinical manifestations of the disease creates certain difficulties in the early diagnosis of HCC. Although HCC screening is most commonly used to determine the level of alpha-fetoprotein (AFP), ultrasound (US), bolus CT and MRI, experience in the use of radionuclide imaging diagnostics, including positron emission tomography, is important in clinical practice (PET), which, not being the main method of primary diagnosis of HCC, however, confirmed their relevance in the differential diagnosis between a benign tumor and metastasis with unclear diagnostic data, as well as in the process of monitoring treatment and in the diagnosis of distant metastases. Conceptual issues in determining the treatment strategy of patients with HCC, depending on the staging of the disease, the prospects for optimizing treatment strategies and traditional methods of treating HCC in detail and in depth are covered in various publications, including publications of domestic authors. Based on this, the authors of the article limited themselves to a brief analysis of the use of embolization and radiation therapy methods for treating HCC, the active development of which in the last decade, as well as promising early results of treatment, suggest that radiation therapy can be considered as the main treatment method for HCC traditional methods. Further study and development of radionuclide methods for the diagnosis and therapy of HCC, as well as the search and study of new radiopharmaceuticals for diagnosis and regional intraarterial radiotherapy is one of the promising directions in modern approaches to the diagnosis and treatment of HCC.

Sign in / Sign up

Export Citation Format

Share Document